{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:56:57Z","timestamp":1787497017832,"version":"build-2736575974"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Autosomal Dominant Polycystic Kidney Disease (ADPKD) affects up to 70 000 people in the UK and the most common inherited cause of end-stage kidney disease (ESKD). It is generally a late-onset multisystem disorder characterised by bilateral kidney cysts, liver cysts and an increased risk of intracranial aneurysms. Approximately 50% of people with ADPKD reach ESKD by age 60. Disease-associated pain, discomfort, fatigue, emotional distress and, impaired mobility can impact health-related quality of life. The approval of tolvaptan, a vasopressin V2 receptor antagonist, has greatly advanced the care for people with ADPKD, shifting the focus from general chronic kidney disease management to targeted therapeutic approaches. While guidance from NICE and SMC provides a foundational framework, this is not clear or comprehensive enough to offer practical guidance for healthcare professionals in real-world settings. This commentary expands on the previous United Kingdom Kidney Association (UKKA) commentary in 2016 with an updated evidence base, the incorporation of real-world data and expert opinion to provide practical guidance to healthcare professionals. Through co-development with people affected by ADPKD, it now incorporates valuable patient perspectives and offers practical recommendations for the UK kidney community seeking to harmonise the quality of care of all people with ADPKD.<\/jats:p>","DOI":"10.1186\/s12882-025-03960-4","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T03:51:02Z","timestamp":1739505062000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Commentary: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) - an update"],"prefix":"10.1186","volume":"26","author":[{"given":"Matt","family":"Gittus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Haley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tess","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Borrows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Padmanabhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roslyn","family":"Simms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Acquaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert CM","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"issue":"4","key":"3960_CR1","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1111\/j.1523-1755.2005.00201.x","volume":"67","author":"ACM Ong","year":"2005","unstructured":"Ong ACM, Harris PC. Molecular pathogenesis of ADPKD: the polycystin complex gets complex. Kidney Int. 2005;67(4):1234\u201347.","journal-title":"Kidney Int"},{"issue":"6","key":"3960_CR2","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S0272-6386(83)80044-4","volume":"2","author":"CG Iglesias","year":"1983","unstructured":"Iglesias CG, Torres VE, Offord KP, Holley KE, Beard CM, Kurland LT. Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935\u20131980. Am J Kidney Dis. 1983;2(6):630\u20139.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"3960_CR3","doi-asserted-by":"publisher","first-page":"e0190430","DOI":"10.1371\/journal.pone.0190430","volume":"13","author":"A Solazzo","year":"2018","unstructured":"Solazzo A, Testa F, Giovanella S, Busutti M, Furci L, Carrera P, et al. The prevalence of autosomal dominant polycystic kidney disease (ADPKD): a meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition. PLoS ONE. 2018;13(1):e0190430.","journal-title":"PLoS ONE"},{"issue":"8","key":"3960_CR4","first-page":"1356","volume":"32","author":"CJ Willey","year":"2017","unstructured":"Willey CJ, Blais JD, Hall AK, Krasa HB, Makin AJ, Czerwiec FS. Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol Dialysis Transplant. 2017;32(8):1356\u201363.","journal-title":"Nephrol Dialysis Transplant"},{"issue":"6","key":"3960_CR5","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/ndt\/gfs551","volume":"28","author":"HP Neumann","year":"2013","unstructured":"Neumann HP, Jilg C, Bacher J, Nabulsi Z, Malinoc A, Hummel B, et al. Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany. Nephrol Dialysis Transplant. 2013;28(6):1472\u201387.","journal-title":"Nephrol Dialysis Transplant"},{"issue":"5","key":"3960_CR6","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1681\/ASN.2011101032","volume":"23","author":"S Rossetti","year":"2012","unstructured":"Rossetti S, Hopp K, Sikkink RA, Sundsbak JL, Lee YK, Kubly V, et al. Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. J Am Soc Nephrol. 2012;23(5):915\u201333.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"3960_CR7","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1681\/ASN.2015050583","volume":"27","author":"CM Heyer","year":"2016","unstructured":"Heyer CM, Sundsbak JL, Abebe KZ, Chapman AB, Torres VE, Grantham JJ, et al. Predicted mutation strength of nontruncating PKD1 mutations aids genotype-phenotype correlations in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2016;27(9):2872\u201384.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"3960_CR8","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1681\/ASN.2012070650","volume":"24","author":"E Cornec-Le Gall","year":"2013","unstructured":"Cornec-Le Gall E, Audr\u00e9zet MP, Chen JM, Hourmant M, Morin MP, Perrichot R, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol. 2013;24(6):1006\u201313.","journal-title":"J Am Soc Nephrol"},{"key":"3960_CR9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1159\/000421651","volume":"97","author":"DJ Peters","year":"1992","unstructured":"Peters DJ, Sandkuijl LA. Genetic heterogeneity of polycystic kidney disease in Europe. Contrib Nephrol. 1992;97:128\u201339.","journal-title":"Contrib Nephrol"},{"issue":"6","key":"3960_CR10","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1681\/ASN.2015060648","volume":"27","author":"Y-H Hwang","year":"2016","unstructured":"Hwang Y-H, Conklin J, Chan W, Roslin NM, Liu J, He N, et al. Refining genotype-phenotype correlation in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2016;27(6):1861\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"3960_CR11","unstructured":"Harris PC, Torres VE. Polycystic kidney disease, autosomal dominant. 2018."},{"issue":"1","key":"3960_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","volume":"4","author":"C Bergmann","year":"2018","unstructured":"Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJ, Torres VE. Polycystic kidney disease. Nat Rev Dis Primers. 2018;4(1):50.","journal-title":"Nat Rev Dis Primers"},{"issue":"9981","key":"3960_CR13","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/S0140-6736(15)60907-2","volume":"385","author":"AC Ong","year":"2015","unstructured":"Ong AC, Devuyst O, Knebelmann B, Walz G. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet. 2015;385(9981):1993\u20132002.","journal-title":"Lancet"},{"issue":"15","key":"3960_CR14","doi-asserted-by":"publisher","first-page":"e138724","DOI":"10.1172\/jci.insight.138724","volume":"5","author":"S Lavu","year":"2020","unstructured":"Lavu S, Vaughan LE, Senum SR, Kline TL, Chapman AB, Perrone RD, et al. The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD. JCI Insight. 2020;5(15):e138724.","journal-title":"JCI Insight"},{"issue":"2","key":"3960_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1053\/j.ajkd.2017.08.020","volume":"71","author":"D Oberdhan","year":"2018","unstructured":"Oberdhan D, Cole JC, Krasa HB, Cheng R, Czerwiec FS, Hays RD, et al. Development of the autosomal dominant polycystic kidney disease impact scale: a new health-related quality-of-life instrument. Am J Kidney Dis. 2018;71(2):225\u201335.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"3960_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/1471-2369-14-179","volume":"14","author":"T Suwabe","year":"2013","unstructured":"Suwabe T, Ubara Y, Mise K, Kawada M, Hamanoue S, Sumida K, et al. Quality of life of patients with ADPKD\u2014Toranomon PKD QOL study: cross-sectional study. BMC Nephrol. 2013;14(1):179.","journal-title":"BMC Nephrol"},{"issue":"3","key":"3960_CR17","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1053\/j.akdh.2023.01.002","volume":"30","author":"M Gittus","year":"2023","unstructured":"Gittus M, Harris T, Ong AC. Patient perspectives on ADPKD. Adv Kidney Dis Health. 2023;30(3):294\u2013302.","journal-title":"Adv Kidney Dis Health"},{"issue":"5","key":"3960_CR18","doi-asserted-by":"publisher","first-page":"100813","DOI":"10.1016\/j.xkme.2024.100813","volume":"6","author":"E Hoover","year":"2024","unstructured":"Hoover E, Holliday V, Merullo N, Oberdhan D, Perrone RD, Rusconi C, et al. Pain and Health-related quality of life in autosomal dominant polycystic kidney disease: results from a National Patient-Powered Registry. Kidney Med. 2024;6(5):100813.","journal-title":"Kidney Med"},{"issue":"1","key":"3960_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1681\/ASN.2013040398","volume":"25","author":"VE Torres","year":"2014","unstructured":"Torres VE, Harris PC. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol. 2014;25(1):18\u201332.","journal-title":"J Am Soc Nephrol"},{"issue":"25","key":"3960_CR20","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407\u201318.","journal-title":"N Engl J Med"},{"key":"3960_CR21","unstructured":"National Institute for Health and Care Excellence. Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358). 2015."},{"key":"3960_CR22","unstructured":"Scottish Medicines Consortium. Tolvaptan (SMC No. 1114\/1115). 2016."},{"issue":"3","key":"3960_CR23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/ndt\/gfx043","volume":"33","author":"VE Torres","year":"2018","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4: 4 trial. Nephrol Dialysis Transplant. 2018;33(3):477\u201389.","journal-title":"Nephrol Dialysis Transplant"},{"issue":"20","key":"3960_CR24","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377(20):1930\u201342.","journal-title":"N Engl J Med"},{"issue":"10S","key":"3960_CR25","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1681\/ASN.20203110S1490c","volume":"31","author":"VE Torres","year":"2020","unstructured":"Torres VE, Gansevoort RT, Chapman AB, Perrone RD, Ouyang J, Lee J, et al. A Post Hoc Analysis of Tolvaptan (TOL) efficacy and safety in slowing rate of renal function decline in subjects with very late-stage autosomal Dominant polycystic kidney disease (ADPKD): PO1534. J Am Soc Nephrol. 2020;31(10S):490.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3960_CR26","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrology: JASN. 2015;26(1):160.","journal-title":"J Am Soc Nephrology: JASN"},{"issue":"3","key":"3960_CR27","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1681\/ASN.2015010016","volume":"27","author":"E Cornec-Le Gall","year":"2016","unstructured":"Cornec-Le Gall E, Audr\u00e9zet M-P, Rousseau A, Hourmant M, Renaudineau E, Charasse C, et al. The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrology: JASN. 2016;27(3):942.","journal-title":"J Am Soc Nephrology: JASN"},{"issue":"3","key":"3960_CR28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/nrneph.2017.180","volume":"14","author":"AC Ong","year":"2018","unstructured":"Ong AC. Tolvaptan slows disease progression in late-stage ADPKD. Nat Rev Nephrol. 2018;14(3):146\u20138.","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"3960_CR29","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2215\/CJN.01520218","volume":"13","author":"ME Edwards","year":"2018","unstructured":"Edwards ME, Chebib FT, Irazabal MV, Ofstie TG, Bungum LA, Metzger AJ, et al. Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrology: CJASN. 2018;13(8):1153.","journal-title":"Clin J Am Soc Nephrology: CJASN"},{"issue":"7","key":"3960_CR30","doi-asserted-by":"publisher","first-page":"976","DOI":"10.2215\/CJN.00840122","volume":"17","author":"RL McGill","year":"2022","unstructured":"McGill RL, Saunders MR, Hayward AL, Chapman AB. Health disparities in autosomal dominant polycystic kidney disease (ADPKD) in the United States. Clin J Am Soc Nephrol. 2022;17(7):976\u201385.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"3960_CR31","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1681\/ASN.2018060590","volume":"29","author":"FT Chebib","year":"2018","unstructured":"Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrology: JASN. 2018;29(10):2458.","journal-title":"J Am Soc Nephrology: JASN"},{"issue":"3","key":"3960_CR32","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1681\/ASN.2014030297","volume":"26","author":"Y Pei","year":"2015","unstructured":"Pei Y, Hwang Y-H, Conklin J, Sundsbak JL, Heyer CM, Chan W, et al. Imaging-based diagnosis of autosomal dominant polycystic kidney disease. J Am Soc Nephrology: JASN. 2015;26(3):746.","journal-title":"J Am Soc Nephrology: JASN"},{"issue":"2","key":"3960_CR33","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1053\/j.ackd.2009.12.001","volume":"17","author":"Y Pei","year":"2010","unstructured":"Pei Y, Watnick T. Diagnosis and screening of autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis. 2010;17(2):140\u201352.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"5","key":"3960_CR34","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1053\/j.ajkd.2015.07.037","volume":"67","author":"FT Chebib","year":"2016","unstructured":"Chebib FT, Torres VE. Autosomal Dominant polycystic kidney disease: core curriculum 2016. Am J Kidney Dis. 2016;67(5):792\u2013810.","journal-title":"Am J Kidney Dis"},{"key":"3960_CR35","unstructured":"NHS England. The structure of the NHS Genomic Medicine Service 2023. Available from: https:\/\/www.england.nhs.uk\/genomics\/the-structure-of-the-nhs-genomic-medicine-service\/."},{"key":"3960_CR36","unstructured":"NHS National Services Scotland. SSNGM rare and inherited disease test directory 2023. Available from: https:\/\/www.nss.nhs.scot\/publications\/ssngm-rare-and-inherited-disease-test-directory\/."},{"key":"3960_CR37","unstructured":"All Wales Medical Genomics Service. All Wales medical genomic service 2023. Available from: https:\/\/medicalgenomicswales.co.uk\/index.php\/download-services."},{"key":"3960_CR38","unstructured":"Belfast Health and Social Care Trust. Clinical genetics service 2023. Available from: https:\/\/belfasttrust.hscni.net\/service\/laboratory-services\/clinical-genetics\/."},{"issue":"1","key":"3960_CR39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2215\/CJN.0000000000000022","volume":"18","author":"D Mekahli","year":"2023","unstructured":"Mekahli D, Guay-Woodford LM, Cadnapaphornchai MA, Greenbaum LA, Litwin M, Seeman T, et al. Tolvaptan for children and adolescents with autosomal dominant polycystic kidney disease: randomized controlled trial. Clin J Am Soc Nephrol. 2023;18(1):36\u201346.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"3960_CR40","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/ndt\/gfab312","volume":"37","author":"R-U M\u00fcller","year":"2022","unstructured":"M\u00fcller R-U, Messchendorp AL, Birn H, Capasso G, Cornec-Le Gall E, Devuyst O, et al. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European rare kidney Disease Reference Network and polycystic kidney Disease International. Nephrol Dialysis Transplant. 2022;37(5):825\u201339.","journal-title":"Nephrol Dialysis Transplant"},{"key":"3960_CR41","unstructured":"National Kidney Foundation. Diagnostic tests & procedures - Estimated glomerular filtration rate 2022. Available from: https:\/\/www.kidney.org\/sites\/default\/files\/01-10-8374_2212_patflyer_egfr.pdf."},{"key":"3960_CR42","unstructured":"Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Abad JM, et al. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival\u2014an analysis of data from the ERA-EDTA Registry. Nephrol Dialysis Transplant. 2014;29(suppl4):iv15\u201325."},{"issue":"11","key":"3960_CR43","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.2215\/CJN.03650318","volume":"13","author":"AL Messchendorp","year":"2018","unstructured":"Messchendorp AL, van Londen M, Taylor JM, de Borst MH, Navis G, Casteleijn NF, et al. Kidney function reserve capacity in early and later stage autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrology: CJASN. 2018;13(11):1680.","journal-title":"Clin J Am Soc Nephrology: CJASN"},{"key":"3960_CR44","doi-asserted-by":"publisher","first-page":"1009358","DOI":"10.3389\/fmed.2022.1009358","volume":"9","author":"S Th\u00f6ni","year":"2022","unstructured":"Th\u00f6ni S, Keller F, Denicol\u00f2 S, Buchwinkler L, Mayer G. Biological variation and reference change value of the estimated glomerular filtration rate in humans: a systematic review and meta-analysis. Front Med. 2022;9:1009358.","journal-title":"Front Med"},{"issue":"5","key":"3960_CR45","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.kint.2018.12.023","volume":"95","author":"S Alan","year":"2019","unstructured":"Alan S, Shen C, Landsittel DP, Grantham JJ, Cook LT, Torres VE, et al. Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease. Kidney Int. 2019;95(5):1253\u201361.","journal-title":"Kidney Int"},{"issue":"3","key":"3960_CR46","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1053\/j.ackd.2013.01.012","volume":"20","author":"KL Cheung","year":"2013","unstructured":"Cheung KL, Lafayette RA. Renal physiology of pregnancy. Adv Chronic Kidney Dis. 2013;20(3):209\u201314.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"1","key":"3960_CR47","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/ckj\/sfx071","volume":"11","author":"RU M\u00fcller","year":"2018","unstructured":"M\u00fcller RU, Haas CS, Sayer JA. Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan. Clin Kidney J. 2018;11(1):62\u20139.","journal-title":"Clin Kidney J"},{"issue":"11","key":"3960_CR48","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1681\/ASN.2013111184","volume":"25","author":"RW Schrier","year":"2014","unstructured":"Schrier RW, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Friend K, Gitomer B, et al. Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol. 2014;25(11):2399\u2013418.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3960_CR49","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/ki.2015.71","volume":"88","author":"H Bhutani","year":"2015","unstructured":"Bhutani H, Smith V, Rahbari-Oskoui F, Mittal A, Grantham JJ, Torres VE, et al. A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney Int. 2015;88(1):146\u201351.","journal-title":"Kidney Int"},{"issue":"2","key":"3960_CR50","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1053\/j.ajkd.2020.12.020","volume":"78","author":"FT Chebib","year":"2021","unstructured":"Chebib FT, Torres VE. Assessing risk of rapid progression in autosomal dominant polycystic kidney disease and special considerations for disease-modifying therapy. Am J Kidney Dis. 2021;78(2):282\u201392.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"3960_CR51","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1093\/ndt\/gfad270","volume":"39","author":"EW Chen","year":"2024","unstructured":"Chen EW, Chong J, Valluru MK, Durkie M, Simms RJ, Harris PC, et al. Combining genotype with height-adjusted kidney length predicts rapid progression of ADPKD. Nephrol Dialysis Transplantat. 2024;39(6):956\u201366.","journal-title":"Nephrol Dialysis Transplantat"},{"issue":"3","key":"3960_CR52","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2215\/CJN.09500911","volume":"7","author":"AB Chapman","year":"2012","unstructured":"Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrology: CJASN. 2012;7(3):479.","journal-title":"Clin J Am Soc Nephrology: CJASN"},{"key":"3960_CR53","unstructured":"Ministry of Health WaLoJ-PRD. Polycystic kidney disease clinical guideline. 2010."},{"key":"3960_CR54","unstructured":"Otsuka. Jinarc (tolvaptan) prescribing checklist for treatment initiation (section A) & patient monitoring (section B) 2020. Available from: https:\/\/www.hpra.ie\/img\/uploaded\/swedocuments\/f75b8830-1618-4094-98f3-b688c0819ef4.pdf."},{"key":"3960_CR55","unstructured":"Otsuka. Full prescribing information JYNARQUE. 2009. Available from: https:\/\/www.otsuka-us.com\/sites\/g\/files\/qhldwo7076\/files\/media\/static\/JYNARQUE-PI.pdf."},{"key":"3960_CR56","unstructured":"TEVA UK. Tolvaptan TEVA - patient\/carer education brochure 2021. Available from: https:\/\/www.medicines.org.uk\/emc\/files\/pil.12631.pdf."},{"issue":"4","key":"3960_CR57","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1365-2125.2011.04114.x","volume":"73","author":"SE Shoaf","year":"2012","unstructured":"Shoaf SE, Bricmont P, Mallikaarjun S. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. Br J Clin Pharmacol. 2012;73(4):579\u201387.","journal-title":"Br J Clin Pharmacol"},{"key":"3960_CR58","unstructured":"Monthly Index of Medical Specialties (MIMS). Tolvaptan - Full prescribing info 2024. Available from: https:\/\/www.mims.com\/hongkong\/drug\/info\/jinarc?type=full."},{"key":"3960_CR59","unstructured":"British National Formulary. Tolvaptan - Medicinal forms 2023. Available from: https:\/\/bnf.nice.org.uk\/drugs\/tolvaptan\/medicinal-forms\/."},{"key":"3960_CR60","unstructured":"Otsuka. Product monograph - Jinarc (tolvaptan) 2015. Available from: https:\/\/pdf.hres.ca\/dpd_pm\/00053695.PDF."},{"key":"3960_CR61","unstructured":"National Institute for Health and Care Excellence. Angiotensin-converting enzyme (ACE) inhibitors 2024. Available from: https:\/\/cks.nice.org.uk\/topics\/heart-failure-chronic\/prescribing-information\/ace-inhibitors\/."},{"key":"3960_CR62","unstructured":"TEVA pharmaceuticals. Tolvaptan - package leaflet: information for the user 2023. Available from: https:\/\/www.medicines.org.uk\/emc\/files\/pil.12631.pdf."},{"key":"3960_CR63","unstructured":"Electronic Medicines Compendium. Tolvaptan TEVA 15\u00a0mg\u2009+\u200945\u00a0mg tablets 2023. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/12631\/smpc\/print."},{"key":"3960_CR64","unstructured":"Medicines Complete. Medicines complete 2024. Available from: https:\/\/www.medicinescomplete.com\/log-in\/#\/browse\/martindale."},{"key":"3960_CR65","unstructured":"UpToDate T. 2024. Available from: https:\/\/store.wolterskluwercdi.com\/CDI."},{"issue":"5","key":"3960_CR66","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1681\/ASN.2016040448","volume":"28","author":"O Devuyst","year":"2017","unstructured":"Devuyst O, Chapman AB, Gansevoort RT, Higashihara E, Perrone RD, Torres VE, et al. Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3: 4 trial. J Am Soc Nephrology: JASN. 2017;28(5):1592.","journal-title":"J Am Soc Nephrology: JASN"},{"issue":"1","key":"3960_CR67","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.kint.2018.11.044","volume":"96","author":"RT Gansevoort","year":"2019","unstructured":"Gansevoort RT, van Gastel MD, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, et al. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney Int. 2019;96(1):159\u201369.","journal-title":"Kidney Int"},{"issue":"5","key":"3960_CR68","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1001\/archinte.160.5.685","volume":"160","author":"GL Bakris","year":"2000","unstructured":"Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor\u2013associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160(5):685\u201393.","journal-title":"Arch Intern Med"},{"issue":"3","key":"3960_CR69","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/ki.2011.79","volume":"80","author":"FA Holtkamp","year":"2011","unstructured":"Holtkamp FA, De Zeeuw D, Thomas MC, Cooper ME, De Graeff PA, Hillege HJ, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 2011;80(3):282\u20137.","journal-title":"Kidney Int"},{"key":"3960_CR70","doi-asserted-by":"crossref","unstructured":"Raina R, Houry A, Rath P, Mangat G, Pandher D, Islam M et al. Clinical utility and tolerability of tolvaptan in the treatment of autosomal dominant polycystic kidney disease (ADPKD). Drug, healthcare and patient safety. 2022:147\u2009\u2013\u200959.","DOI":"10.2147\/DHPS.S338050"},{"issue":"10","key":"3960_CR71","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.2215\/CJN.03530411","volume":"6","author":"E Higashihara","year":"2011","unstructured":"Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, et al. Tolvaptan in autosomal dominant polycystic kidney disease: three years\u2019 experience. Clin J Am Soc Nephrology: CJASN. 2011;6(10):2499.","journal-title":"Clin J Am Soc Nephrology: CJASN"},{"key":"3960_CR72","unstructured":"Medicines & Healthcare products Regulatory Agency. Yellow card - Information unknown. Available from: https:\/\/yellowcard.mhra.gov.uk\/information."},{"issue":"9","key":"3960_CR73","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/bph.14630","volume":"176","author":"Y Ali","year":"2019","unstructured":"Ali Y, Dohi K, Okamoto R, Katayama K, Ito M. Novel molecular mechanisms in the inhibition of adrenal aldosterone synthesis: action of tolvaptan via vasopressin V2 receptor-independent pathway. Br J Pharmacol. 2019;176(9):1315\u201327.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"3960_CR74","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40265-019-1056-1","volume":"79","author":"HA Blair","year":"2019","unstructured":"Blair HA, Tolvaptan. A review in autosomal dominant polycystic kidney disease. Drugs. 2019;79(3):303\u201313.","journal-title":"Drugs"},{"issue":"3","key":"3960_CR75","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1053\/j.ajkd.2018.09.016","volume":"73","author":"BJ Kramers","year":"2019","unstructured":"Kramers BJ, van Gastel MD, Boertien WE, Meijer E, Gansevoort RT. Determinants of urine volume in ADPKD patients using the vasopressin V2 receptor antagonist tolvaptan. Am J Kidney Dis. 2019;73(3):354\u201362.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"3960_CR76","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1053\/j.ajkd.2016.07.023","volume":"68","author":"OW Amro","year":"2016","unstructured":"Amro OW, Paulus JK, Noubary F, Perrone RD. Low-osmolar diet and adjusted water intake for vasopressin reduction in autosomal dominant polycystic kidney disease: a pilot randomized controlled trial. Am J Kidney Dis. 2016;68(6):882\u201391.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"3960_CR77","doi-asserted-by":"publisher","first-page":"151405","DOI":"10.1016\/j.semnephrol.2023.151405","volume":"43","author":"K Lambert","year":"2023","unstructured":"Lambert K, Gardos R, Coolican H, Pickel L, Sung HK, Wang AY, et al. Diet and polycystic kidney disease: nutrients, foods, dietary patterns, and implications for practice. Semin Nephrol. 2023;43(2):151405.","journal-title":"Semin Nephrol"},{"issue":"4","key":"3960_CR78","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.kint.2020.04.053","volume":"98","author":"BJ Kramers","year":"2020","unstructured":"Kramers BJ, Koorevaar IW, Drenth JPH, de Fijter JW, Neto AG, Peters DJM, et al. Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease. Kidney Int. 2020;98(4):989\u201398.","journal-title":"Kidney Int"},{"issue":"5","key":"3960_CR79","first-page":"e25045","volume":"14","author":"O Tarabzuni","year":"2022","unstructured":"Tarabzuni O, Tarabzuni O. The effect of dietary intervention on autosomal-dominant polycystic kidney disease (ADPKD) patients on Tolvaptan and their quality of life. Cureus. 2022;14(5):e25045.","journal-title":"Cureus"},{"issue":"1","key":"3960_CR80","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/ki.2013.444","volume":"85","author":"A Levin","year":"2014","unstructured":"Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014;85(1):49\u201361.","journal-title":"Kidney Int"},{"key":"3960_CR81","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fnut.2017.00040","volume":"4","author":"AD Seal","year":"2017","unstructured":"Seal AD, Bardis CN, Gavrieli A, Grigorakis P, Adams J, Arnaoutis G, et al. Coffee with high but not low caffeine content augments fluid and electrolyte excretion at rest. Front Nutr. 2017;4:40.","journal-title":"Front Nutr"},{"key":"3960_CR82","doi-asserted-by":"crossref","unstructured":"Meca R, Balbo BE, Ormanji MS, Fonseca JM, Iannuzzi LR, Costa ES et al. Caffeine accelerates cystic kidney disease in a Pkd1-deficient mouse model. Cell Physiol Biochem. 2019;52(5):1061\u201374.","DOI":"10.33594\/000000072"},{"key":"3960_CR83","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40620-017-0396-8","volume":"31","author":"L Girardat-Rotar","year":"2018","unstructured":"Girardat-Rotar L, Puhan MA, Braun J, Serra AL. Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a prospective longitudinal cohort study. J Nephrol. 2018;31:87\u201394.","journal-title":"J Nephrol"},{"key":"3960_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-018-1182-0","volume":"19","author":"KA McKenzie","year":"2018","unstructured":"McKenzie KA, El Ters M, Torres VE, Harris PC, Chapman AB, Mrug M, et al. Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort. BMC Nephrol. 2018;19:1\u201310.","journal-title":"BMC Nephrol"},{"key":"3960_CR85","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1590\/S0100-879X2012007500120","volume":"45","author":"L Vendramini","year":"2012","unstructured":"Vendramini L, Nishiura J, Baxmann A, Heilberg I. Caffeine intake by patients with autosomal dominant polycystic kidney disease. Braz J Med Biol Res. 2012;45:834\u201340.","journal-title":"Braz J Med Biol Res"},{"issue":"1","key":"3960_CR86","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12882-018-0957-7","volume":"19","author":"BJ Kramers","year":"2018","unstructured":"Kramers BJ, van Gastel MDA, Meijer E, Gansevoort RT. Case report: a thiazide diuretic to treat polyuria induced by tolvaptan. BMC Nephrol. 2018;19(1):157.","journal-title":"BMC Nephrol"},{"issue":"4","key":"3960_CR87","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2215\/CJN.11260821","volume":"17","author":"BJ Kramers","year":"2022","unstructured":"Kramers BJ, Koorevaar IW, van Gastel MD, van Goor H, Hallows KR, Heerspink HL, et al. Effects of hydrochlorothiazide and metformin on aquaresis and nephroprotection by a vasopressin V2 receptor antagonist in ADPKD: a randomized crossover trial. Clin J Am Soc Nephrol. 2022;17(4):507\u201317.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"3960_CR88","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.21873\/invivo.12924","volume":"36","author":"I Capelli","year":"2022","unstructured":"Capelli I, Iacovella F, Ghedini L, Aiello V, Napoletano A, Marconi L, et al. A case report of tolvaptan therapy for ADPKD patients with COVID-19. The need for appropriate counselling for temporary drug discontinuation. In Vivo. 2022;36(4):1994\u20137.","journal-title":"In Vivo"},{"key":"3960_CR89","unstructured":"Think Kidneys. Sick day guidance in patients at risk of acute kidney injury: a position statement from the Think Kidneys board 2018. Available from: https:\/\/www.thinkkidneys.nhs.uk\/aki\/wp-content\/uploads\/sites\/2\/2018\/01\/Think-Kidneys-Sick-Day-Guidance-2018.pdf."},{"issue":"19","key":"3960_CR90","doi-asserted-by":"publisher","first-page":"6341","DOI":"10.3390\/jcm12196341","volume":"12","author":"F Morioka","year":"2023","unstructured":"Morioka F, Nakatani S, Uedono H, Tsuda A, Mori K, Emoto M. Short-term dapagliflozin administration in autosomal dominant polycystic kidney disease\u2014A retrospective single-arm case series study. J Clin Med. 2023;12(19):6341.","journal-title":"J Clin Med"},{"issue":"3","key":"3960_CR91","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1053\/j.ajkd.2022.08.012","volume":"81","author":"DH Alpers","year":"2023","unstructured":"Alpers DH, Lewis JH, Hunt CM, Freston JW, Torres VE, Li H, et al. Clinical pattern of tolvaptan-associated liver injury in trial participants with autosomal dominant polycystic kidney disease (ADPKD): an analysis of pivotal clinical trials. Am J Kidney Dis. 2023;81(3):281\u201393. e1.","journal-title":"Am J Kidney Dis"},{"key":"3960_CR92","unstructured":"Attalah E, A GP. Drug-induced liver injury 2023. Available from: https:\/\/www.bsg.org.uk\/web-education-articles-list\/drug-induced-liver-injury\/."},{"key":"3960_CR93","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","volume":"38","author":"PB Watkins","year":"2015","unstructured":"Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, et al. Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf. 2015;38:1103\u201313.","journal-title":"Drug Saf"},{"issue":"1","key":"3960_CR94","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/gutjnl-2017-314924","volume":"67","author":"PN Newsome","year":"2018","unstructured":"Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, et al. Guidelines on the management of abnormal liver blood tests. Gut. 2018;67(1):6\u201319.","journal-title":"Gut"},{"issue":"Suppl 6","key":"3960_CR95","doi-asserted-by":"publisher","first-page":"s104","DOI":"10.7861\/clinmedicine.16-6-s104","volume":"16","author":"D Katarey","year":"2016","unstructured":"Katarey D, Verma S. Drug-induced liver injury. Clin Med. 2016;16(Suppl 6):s104.","journal-title":"Clin Med"},{"issue":"3","key":"3960_CR96","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1503\/cmaj.1040752","volume":"172","author":"EG Giannini","year":"2005","unstructured":"Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005;172(3):367\u201379.","journal-title":"CMAJ"},{"key":"3960_CR97","doi-asserted-by":"publisher","first-page":"987092","DOI":"10.3389\/fmed.2022.987092","volume":"9","author":"J Naranjo","year":"2022","unstructured":"Naranjo J, Borrego F, Rocha JL, Salgueira M, Mart\u00edn-Gomez MA, Orellana C, et al. Real clinical experience after one year of treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease. Front Med (Lausanne). 2022;9:987092.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"3960_CR98","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.3390\/ijms25042088","volume":"25","author":"M Yamazaki","year":"2024","unstructured":"Yamazaki M, Kawano H, Miyoshi M, Kimura T, Takahashi K, Muto S, et al. Long-Term effects of Tolvaptan in autosomal dominant polycystic kidney disease: predictors of treatment response and safety over 6 years of continuous therapy. Int J Mol Sci. 2024;25(4):2088.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3960_CR99","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/ki.2011.119","volume":"80","author":"MV Irazabal","year":"2011","unstructured":"Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG, et al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2011;80(3):295\u2013301.","journal-title":"Kidney Int"},{"issue":"7","key":"3960_CR100","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1681\/ASN.2020101512","volume":"32","author":"JE Heida","year":"2021","unstructured":"Heida JE, Gansevoort RT, Torres VE, Devuyst O, Perrone RD, Lee J, et al. The effect of tolvaptan on BP in polycystic kidney disease: a post hoc analysis of the TEMPO 3: 4 trial. J Am Soc Nephrol. 2021;32(7):1801\u201312.","journal-title":"J Am Soc Nephrol"},{"key":"3960_CR101","unstructured":"Samsca. Tolvaptan - Effect on fluid balance 2021. Available from: https:\/\/www.samsca.com\/hyponatremia-heart-failure\/efficacy\/fluid-balance."},{"key":"3960_CR102","unstructured":"European Medicines Agency. Assessment report - Jinarc 2015. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/jinarc-epar-public-assessment-report_en.pdf."},{"key":"3960_CR103","unstructured":"National Health Service. Visiting an opticians 2023. Available from: https:\/\/www.nhs.uk\/nhs-services\/opticians\/visiting-an-optician\/#:~:text=The%20NHS%20recommends%20that%20you,test%20is%20considered%20clinically%20necessary."},{"issue":"10","key":"3960_CR104","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1136\/emermed-2019-208409","volume":"36","author":"I Popovich","year":"2019","unstructured":"Popovich I, Szecket N, Nahill A. Framing of clinical information affects physicians\u2019 diagnostic accuracy. Emerg Med J. 2019;36(10):589\u201394.","journal-title":"Emerg Med J"},{"issue":"1","key":"3960_CR105","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.pec.2007.11.004","volume":"71","author":"S Almashat","year":"2008","unstructured":"Almashat S, Ayotte B, Edelstein B, Margrett J. Framing effect debiasing in medical decision making. Patient Educ Couns. 2008;71(1):102\u20137.","journal-title":"Patient Educ Couns"},{"key":"3960_CR106","first-page":"20","volume":"12","author":"J Gong","year":"2013","unstructured":"Gong J, Zhang Y, Feng J, Huang Y, Wei Y, Zhang W. Influence of framing on medical decision making. Excli J. 2013;12:20\u20139.","journal-title":"Excli J"},{"issue":"1","key":"3960_CR107","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12882-019-1290-5","volume":"20","author":"H Bennett","year":"2019","unstructured":"Bennett H, McEwan P, Hamilton K, O\u2019Reilly K. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model. BMC Nephrol. 2019;20(1):136.","journal-title":"BMC Nephrol"},{"key":"3960_CR108","unstructured":"UK Government. Reasonable adjustments for workers with disabilities or health conditions 2023. Available from: https:\/\/www.gov.uk\/reasonable-adjustments-for-disabled-workers."},{"issue":"1","key":"3960_CR109","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/ckj\/sfac190","volume":"16","author":"J Chong","year":"2023","unstructured":"Chong J, Harris T, Ong AC. Regional variation in tolvaptan prescribing across England: national data and retrospective evaluation from an expert centre. Clin Kidney J. 2023;16(1):61\u20138.","journal-title":"Clin Kidney J"},{"issue":"2","key":"3960_CR110","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ekir.2023.10.029","volume":"9","author":"J Taylor","year":"2024","unstructured":"Taylor J, Thomas R, Metherall P, van Gastel M, Cornec-Le Gall E, Caroli A, et al. An Artificial Intelligence Generated Automated Algorithm to measure total kidney volume in ADPKD. Kidney Int Rep. 2024;9(2):249\u201356.","journal-title":"Kidney Int Rep"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-03960-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-03960-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-03960-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T15:38:08Z","timestamp":1739547488000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-03960-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":110,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3960"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-03960-4","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval was sought for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was given by the UKKA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"79"}}